Coupling to short linear motifs creates versatile PME-1 activities in PP2A holoenzyme demethylation and inhibition

  1. Yitong Li
  2. Vijaya Kumar Balakrishnan
  3. Michael Rowse
  4. Cheng-Guo Wu
  5. Anastasia Phoebe Bravos
  6. Vikash K Yadav
  7. YIva Ivarsson
  8. Stefan Strack
  9. Irina V Novikova
  10. Yongna Xing  Is a corresponding author
  1. University of Wisconsin-Madison, United States
  2. Indiana University - Purdue University Columbus, United States
  3. Uppsala University, Sweden
  4. University of Iowa, United States
  5. Pacific Northwest National Laboratory, United States

Abstract

Protein phosphatase 2A (PP2A) holoenzymes target broad substrates by recognizing short motifs via regulatory subunits. PP2A methylesterase 1 (PME-1) is a cancer-promoting enzyme and undergoes methylesterase activation upon binding to the PP2A core enzyme. Here we showed that PME-1 readily demethylates different families of PP2A holoenzymes and blocks substrate recognition in vitro. The high-resolution cryo-EM structure of a PP2A-B56 holoenzyme-PME-1 complex reveals that PME-1 disordered regions, including a substrate-mimicking motif, tether to the B56 regulatory subunit at remote sites. They occupy the holoenzyme substrate-binding groove and allow large structural shifts in both holoenzyme and PME-1 to enable multi-partite contacts at structured cores to activate the methylesterase. B56-interface mutations selectively block PME-1 activity toward PP2A-B56 holoenzymes and affect the methylation of a fraction of total cellular PP2A. The B56-interface mutations allow us to uncover B56-specific PME-1 functions in p53 signaling. Our studies reveal multiple mechanisms of PME-1 in suppressing holoenzyme functions and versatile PME-1 activities derived from coupling substrate-mimicking motifs to dynamic structured cores.

Data availability

All data are available in the main text or in the supplementary materials. The cryo-EM map and the refined atomic model of PP2A-B56γ1-PME-1 complex has been deposited at EMDB (https://www.ebi.ac.uk/https://www.ebi.ac.uk/) and RCSB (https://www.rcsb.org/) under the accession codes of EMD-25363 and 7SOY, respectively.

Article and author information

Author details

  1. Yitong Li

    Department of Oncology, University of Wisconsin-Madison, Madison, United States
    Competing interests
    The authors declare that no competing interests exist.
  2. Vijaya Kumar Balakrishnan

    Department of Oncology, University of Wisconsin-Madison, Madison, United States
    Competing interests
    The authors declare that no competing interests exist.
  3. Michael Rowse

    Indiana University - Purdue University Columbus, Columbus, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-5572-5258
  4. Cheng-Guo Wu

    Department of Oncology, University of Wisconsin-Madison, Madison, United States
    Competing interests
    The authors declare that no competing interests exist.
  5. Anastasia Phoebe Bravos

    Department of Oncology, University of Wisconsin-Madison, Madison, United States
    Competing interests
    The authors declare that no competing interests exist.
  6. Vikash K Yadav

    5Department of Chemistry, Uppsala University, Uppsala, Sweden
    Competing interests
    The authors declare that no competing interests exist.
  7. YIva Ivarsson

    5Department of Chemistry, Uppsala University, Uppsala, Sweden
    Competing interests
    The authors declare that no competing interests exist.
  8. Stefan Strack

    Department of Neuroscience and Pharmacology, University of Iowa, Iowa City, United States
    Competing interests
    The authors declare that no competing interests exist.
  9. Irina V Novikova

    Environmental Molecular Sciences Laboratory, Pacific Northwest National Laboratory, Richland, United States
    Competing interests
    The authors declare that no competing interests exist.
  10. Yongna Xing

    Department of Oncology, University of Wisconsin-Madison, Madison, United States
    For correspondence
    xing@oncology.wisc.edu
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-9834-528X

Funding

National Institute of General Medical Sciences (GM137090-01 (Y.X.))

  • Yongna Xing

American Cancer Society (RSG-10-153-01-DMC (Y.X.))

  • Yongna Xing

Jordan's Guardian Angels Foundation and Jordan's Syndrome research consortium fund from the State of California (A19-3376-5007 (Y.X.))

  • Yongna Xing

National Institute of General Medical Sciences (GM096060-01 (Y.X.))

  • Yongna Xing

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Reviewing Editor

  1. Jungsan Sohn, Johns Hopkins University School of Medicine, United States

Publication history

  1. Received: April 25, 2022
  2. Preprint posted: July 1, 2022 (view preprint)
  3. Accepted: August 3, 2022
  4. Accepted Manuscript published: August 4, 2022 (version 1)
  5. Version of Record published: August 23, 2022 (version 2)

Copyright

This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.

Metrics

  • 706
    Page views
  • 228
    Downloads
  • 2
    Citations

Article citation count generated by polling the highest count across the following sources: Crossref, PubMed Central, Scopus.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Yitong Li
  2. Vijaya Kumar Balakrishnan
  3. Michael Rowse
  4. Cheng-Guo Wu
  5. Anastasia Phoebe Bravos
  6. Vikash K Yadav
  7. YIva Ivarsson
  8. Stefan Strack
  9. Irina V Novikova
  10. Yongna Xing
(2022)
Coupling to short linear motifs creates versatile PME-1 activities in PP2A holoenzyme demethylation and inhibition
eLife 11:e79736.
https://doi.org/10.7554/eLife.79736

Further reading

    1. Biochemistry and Chemical Biology
    2. Structural Biology and Molecular Biophysics
    Dario Segura-Peña, Oda Hovet ... Nikolina Sekulic
    Research Article Updated

    Aurora B, together with IN-box, the C-terminal part of INCENP, forms an enzymatic complex that ensures faithful cell division. The [Aurora B/IN-box] complex is activated by autophosphorylation in the Aurora B activation loop and in IN-box, but it is not clear how these phosphorylations activate the enzyme. We used a combination of experimental and computational studies to investigate the effects of phosphorylation on the molecular dynamics and structure of [Aurora B/IN-box]. In addition, we generated partially phosphorylated intermediates to analyze the contribution of each phosphorylation independently. We found that the dynamics of Aurora and IN-box are interconnected, and IN-box plays both positive and negative regulatory roles depending on the phosphorylation status of the enzyme complex. Phosphorylation in the activation loop of Aurora B occurs intramolecularly and prepares the enzyme complex for activation, but two phosphorylated sites are synergistically responsible for full enzyme activity.

    1. Biochemistry and Chemical Biology
    2. Structural Biology and Molecular Biophysics
    Maura Greiser, Mariusz Karbowski ... Liron Boyman
    Research Article

    Mitochondrial ATP production in cardiac ventricular myocytes must be continually adjusted to rapidly replenish the ATP consumed by the working heart. Two systems are known to be critical in this regulation: mitochondrial matrix Ca2+ ([Ca2+]m) and blood flow that is tuned by local ventricular myocyte metabolic signaling. However, these two regulatory systems do not fully account for the physiological range of ATP consumption observed. We report here on the identity, location, and signaling cascade of a third regulatory system -- CO2/bicarbonate. CO2 is generated in the mitochondrial matrix as a metabolic waste product of the oxidation of nutrients that powers ATP production. It is a lipid soluble gas that rapidly permeates the inner mitochondrial membrane (IMM) and produces bicarbonate (HCO3-) in a reaction accelerated by carbonic anhydrase (CA). The bicarbonate level is tracked physiologically by a bicarbonate-activated adenylyl cyclase, soluble adenylyl cyclase (sAC). Using structural Airyscan super-resolution imaging and functional measurements we find that sAC is primarily inside the mitochondria of ventricular myocytes where it generates cAMP when activated by HCO3-. Our data strongly suggest that ATP production in these mitochondria is regulated by this cAMP signaling cascade operating within the inter-membrane space (IMS) by activating local EPAC1 (Exchange Protein directly Activated by cAMP) which turns on Rap1 (Ras-related protein 1). Thus, mitochondrial ATP production is shown to be increased by bicarbonate-triggered sAC signaling through Rap1. Additional evidence is presented indicating that the cAMP signaling itself does not occur directly in the matrix. We also show that this third signaling process involving bicarbonate and sAC activates the cardiac mitochondrial ATP production machinery by working independently of, yet in conjunction with, [Ca2+]m-dependent ATP production to meet the energy needs of cellular activity in both health and disease. We propose that the bicarbonate and calcium signaling arms function in a resonant or complementary manner to match mitochondrial ATP production to the full range of energy consumption in cardiac ventricular myocytes in health and disease.